---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-017040"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:55:10.340945+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# GeoVax Q1 net loss widens to $5.6M; cash drops to $0.8M, raising going-concern risk

## Summary
- Net loss of $5.6M ($2.47 per share) vs $4.0M ($2.30 per share) in Q1 2023.
- Cash balance fell to $768,859 from $6.45M at Dec 31, 2023, a decline of ~$5.7M.
- R&D expenses rose to $4.43M from $2.82M, driven by manufacturing costs for clinical trials.
- Phase 2 GEO-CM04S1 COVID vaccine booster trial showed statistically significant neutralizing antibody increases against multiple variants.
- Gedeptin Phase 1/2 for head and neck cancer completed enrollment; expected to complete Q3 2024.

## SEC filing metadata
- accession: 0001437749-24-017040
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774924017040/0001437749-24-017040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774924017040/govx20240514_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-017040
- JSON: https://secwatch.observer/filing/0001437749-24-017040.json
- Plain text: https://secwatch.observer/filing/0001437749-24-017040.txt

## Key facts
- Earnings Releases
  GeoVax Labs, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/832489/000143774924017040/0001437749-24-017040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.